Dientamoebiasis

Infectious Disease MONDO:0024608 Pathograph 14 Show in embeddings browser Protozoal infection Gastrointestinal infection

Dientamoebiasis is a parasitic infection of the large intestine caused by the protozoan Dientamoeba fragilis. It is commonly reported worldwide in association with gastrointestinal symptoms including diarrhea, abdominal pain, and flatulence, though its pathogenicity remains debated. Transmission is thought to occur via the fecal-oral route, possibly facilitated by helminth eggs such as those of Enterobius vermicularis (pinworm). Clinical outcomes range from asymptomatic carriage to chronic gastrointestinal illness.

Ask OpenScientist

Ask a research question about Dientamoebiasis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
10
Phenotypes
1
Gaps
14
Pathograph
4
Medical Actions
5
Differentials
2
Trials
1
References
2
Deep Research
?

Discussions and Knowledge Gaps

1
Is Dientamoeba fragilis a true intestinal pathogen capable of causing gastrointestinal disease, or primarily a commensal organism whose co-detection with symptoms reflects epidemiological coincidence — and does Blastocystis sp. co-infection confound pathogenicity assessments?
KNOWLEDGE GAP OPEN gap_dientamoeba_pathogenicity
Attached to
pathophysiology#Mucosal inflammatory response pathophysiology#Trophozoite colonization of colonic mucosa
The causal pathogenicity of D. fragilis remains unresolved. Evidence supporting pathogenicity: parasite load correlates dose-dependently with symptom severity (PMID:40153748); eosinophilia in familial clusters implicates an immune mechanism (PMID:23759351). Evidence against: two placebo-controlled trials found no clinical benefit from eradication therapy versus placebo or watch-and-wait (PMID:24647023; PMID:39540993), and a 2024 case-control study found no clinical differences between PCR-positive and PCR-negative groups (PMID:39052010). Critically, no specific invasion virulence factors, mucosal histological lesions, or parasite–host contact structures attributable to D. fragilis have been demonstrated in human tissue, unlike Entamoeba histolytica which has well-characterized invasion mechanisms. Blastocystis sp. co-infection (present in ~38% of D. fragilis-positive patients in one cohort, PMID:33137500) further confounds interpretation: Blastocystis carries a stronger epidemiological IBS association than D. fragilis (PMID:28668983), and studies that do not stratify by co-infection status cannot attribute symptoms to either organism alone.
Proposed experiments
Colonoscopy with mucosal biopsy stratified by Blastocystis co-infection
exp_dientamoeba_mucosal_biopsy_stratified
Recruit PCR-confirmed D. fragilis carriers (both symptomatic and asymptomatic) and matched PCR-negative controls, stratified by Blastocystis sp. co-infection status. Perform colonoscopy with mucosal biopsies to assess histological evidence of mucosal injury, lamina propria inflammation, and parasite-host interface zones. Determine whether any inflammatory signal is attributable to D. fragilis independently of Blastocystis co-infection.
Eradication RCT stratified by parasite load and Blastocystis co-infection
exp_dientamoeba_stratified_rct
Design a placebo-controlled eradication trial with pre-specified stratification by quantitative parasite load and Blastocystis co-infection status. Test whether treatment benefit is conditional on high D. fragilis burden or on the absence of Blastocystis, to determine whether current RCT null results reflect genuine commensalism or inadequate subgroup stratification.
⚙

Pathophysiology

4
Trophozoite colonization of colonic mucosa
Dientamoeba fragilis trophozoites establish residence in the lumen and on the mucosal surface of the large intestine. The organism lacks a well-established cyst stage in humans, so trophozoites represent the primary parasitic form in the colon. Colonization may be facilitated by ingestion of contaminated pinworm eggs harboring viable D. fragilis organisms.
Epithelial cell of large intestine CL:0002253 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Epithelial cell of large intestine (CL:0002253). CL:0002253 is a cell type from the Cell Ontology.
Large intestine UBERON:0000059 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Large intestine (UBERON:0000059). UBERON:0000059 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Mucosal inflammatory response Trophozoite colonization of the colonic mucosa triggers local host inflammatory and immune responses.
Show evidence (1 reference)
PMID:27170141 SUPPORT Human Clinical
"Dientamoeba fragilis is a protozoan parasite of the human bowel, commonly reported throughout the world in association with gastrointestinal symptoms."
Confirms D. fragilis colonizes the human bowel.
Mucosal inflammatory response
Colonization by D. fragilis trophozoites is hypothesized to elicit a host immune response involving mucosal inflammation. D. fragilis is non-invasive and the precise virulence factors are poorly characterized; a mucosal inflammatory mechanism is inferred from the clinical symptom association rather than demonstrated histologically, and pathogenicity itself remains contested (see notes). Peripheral eosinophilia has been observed in some patients, suggesting a possible Th2-skewed or allergic-type immune component.
Epithelial cell of large intestine CL:0002253 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Epithelial cell of large intestine (CL:0002253). CL:0002253 is a cell type from the Cell Ontology. Mature eosinophil CL:0000041 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Mature eosinophil (CL:0000041). CL:0000041 is a cell type from the Cell Ontology.
Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED Defense response to protozoan GO:0042832 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Defense response to protozoan (GO:0042832). GO:0042832 is a biological process from the Gene Ontology. ↑ INCREASED
Large intestine UBERON:0000059 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Large intestine (UBERON:0000059). UBERON:0000059 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Altered intestinal motility and secretion Mucosal inflammation leads to disrupted colonic motility and increased secretory activity producing gastrointestinal symptoms.
Systemic immune activation In some patients the inflammatory response extends beyond the gut, producing peripheral eosinophilia and cutaneous manifestations.
Show evidence (5 references)
PMID:21637013 SUPPORT Human Clinical
"Usually, carriage of Dientamoeba is associated with symptoms such as abdominal pain and diarrhea. Moreover, antimicrobial therapy followed by resolution of symptoms coincides with the eradication of Dientamoeba."
Supports the pathogenic role of D. fragilis by linking carriage to symptoms and symptom resolution to eradication after treatment.
PMID:23759351 SUPPORT Human Clinical
"We report a familial cluster of D. fragilis associated with marked peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis infection should be considered in the setting of unexplained eosinophilia."
Reports marked eosinophilia in D. fragilis infection, suggesting an eosinophilic inflammatory component to the host response.
PMID:40153748 SUPPORT Human Clinical
"The proportion of individuals with D fragilis and a parasite load less than 1 trophozoite per field was higher in asymptomatic individuals (controls) than in symptomatic cases (47.7% vs 3.1%, respectively) (P < .001). Parasite load is associated with the presence of gastrointestinal symptoms,..."
Case-control study demonstrating a dose-dependent relationship between parasite load and gastrointestinal symptoms, supporting a pathogenic role for D. fragilis. The paper does not address the underlying mucosal mechanism, which remains uncharacterized.
+ 2 more references
Altered intestinal motility and secretion
Colonic mucosal inflammation caused by D. fragilis leads to altered intestinal motility and increased secretory activity. This manifests clinically as diarrhea, abdominal pain, flatulence, and nausea. The mechanisms likely involve local release of inflammatory mediators that affect smooth muscle contractility and epithelial ion transport.
Inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Large intestine UBERON:0000059 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Large intestine (UBERON:0000059). UBERON:0000059 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Abdominal pain Altered colonic motility can manifest as abdominal pain.
Diarrhea Increased secretory activity and altered colonic motility can manifest as diarrhea.
Flatulence Intestinal dysfunction can manifest as flatulence.
Nausea Intestinal dysfunction can manifest as nausea.
Anorexia Symptomatic intestinal infection can reduce appetite.
Weight loss Persistent gastrointestinal symptoms can be accompanied by weight loss.
Fatigue Persistent symptomatic infection can manifest as fatigue.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Lists the gastrointestinal symptoms resulting from intestinal dysfunction in D. fragilis infection.
Systemic immune activation
In a subset of patients, the immune response to D. fragilis extends beyond the intestinal mucosa, resulting in peripheral eosinophilia and occasionally cutaneous manifestations such as urticaria and pruritus. This may reflect a systemic Th2-type response or IgE-mediated hypersensitivity to parasite antigens.
Mature eosinophil CL:0000041 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Mature eosinophil (CL:0000041). CL:0000041 is a cell type from the Cell Ontology.
Innate immune response GO:0045087 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated Innate immune response (GO:0045087). GO:0045087 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Peripheral eosinophilia Systemic immune activation can present as peripheral eosinophilia.
Pruritus Systemic immune activation can include pruritus.
Urticaria Systemic immune activation can include urticaria.
Show evidence (2 references)
PMID:23759351 SUPPORT Human Clinical
"We report a familial cluster of D. fragilis associated with marked peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis infection should be considered in the setting of unexplained eosinophilia."
Demonstrates systemic immune activation with marked eosinophilia extending beyond the intestinal mucosa.
PMID:10795375 SUPPORT Human Clinical
"Occasionally, eosinophilia, urticaria and pruritus have been described."
Documents extra-intestinal manifestations including eosinophilia, urticaria, and pruritus consistent with systemic immune activation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Dientamoebiasis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Blood 1
Peripheral eosinophilia OCCASIONAL Increased total eosinophil count HP:0001880 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Eosinophilia, annotated with Increased total eosinophil count (HP:0001880). HP:0001880 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23759351 SUPPORT Human Clinical
"We report a familial cluster of D. fragilis associated with marked peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis infection should be considered in the setting of unexplained eosinophilia."
Case report of a family cluster showing marked peripheral eosinophilia associated with D. fragilis infection.
PMID:10795375 SUPPORT Human Clinical
"Occasionally, eosinophilia, urticaria and pruritus have been described."
Review notes occasional eosinophilia in D. fragilis infection.
Cardiovascular 1
Urticaria VERY_RARE HP:0001025 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Urticaria (HP:0001025), qualified as located in Skin of body. HP:0001025 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"Occasionally, eosinophilia, urticaria and pruritus have been described."
Urticaria is reported as an occasional feature of D. fragilis infection.
Digestive 4
Diarrhea FREQUENT HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29404747 SUPPORT Human Clinical
"Data from seven studies of specific populations reported that 22% had D. fragilis in stools of which only 23% had diarrhea. Eleven studies of stool samples submitted to laboratories reported that 4.3% of individuals had D. fragilis of which 54% had diarrhea."
Diarrhea is frequently reported in D. fragilis carriers presenting to laboratories, though prevalence varies by study setting. Evidence that D. fragilis causes diarrhea is inconclusive.
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Review identifies persistent diarrhea as one of the most common symptoms associated with D. fragilis infection.
Flatulence OCCASIONAL HP:0033589 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flatulence (HP:0033589). HP:0033589 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Flatulence is listed among the most common clinical symptoms.
PMID:33137500 SUPPORT Human Clinical
"The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%, watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%."
Meteorism (abdominal bloating/flatulence) was reported at 16.5% in this cohort.
Nausea OCCASIONAL HP:0002018 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nausea (HP:0002018). HP:0002018 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33137500 SUPPORT Human Clinical
"The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%, watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%."
Nausea and lack of appetite were reported at 14.1% of D. fragilis-positive patients.
Anorexia OCCASIONAL HP:0002039 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anorexia (HP:0002039). HP:0002039 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Loss of appetite is identified as a common clinical symptom.
Integument 1
Pruritus OCCASIONAL HP:0000989 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pruritus (HP:0000989), qualified as located in Skin of body. HP:0000989 is a phenotype from the Human Phenotype Ontology.
Anal itching (pruritus ani) has been reported as a surprisingly prevalent symptom in some studies, potentially related to co-infection with Enterobius vermicularis.
Show evidence (2 references)
PMID:33137500 SUPPORT Human Clinical
"The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%, watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%."
Anal itching was the second most prevalent symptom at 27.1%, which was described as unexpectedly common.
PMID:10795375 SUPPORT Human Clinical
"Occasionally, eosinophilia, urticaria and pruritus have been described."
Pruritus is noted as an occasional feature of D. fragilis infection.
Constitutional 2
Abdominal pain OCCASIONAL HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027), qualified as located in Large intestine. HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:33137500 SUPPORT Human Clinical
"The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%, watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%."
Abdominal pain was the most prevalent symptom among D. fragilis-positive patients in this Italian cohort.
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Review identifies abdominal pain as one of the most common symptoms.
Fatigue OCCASIONAL HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:8794799 SUPPORT Human Clinical
"Primarily characterized by diarrhea and abdominal pain, other symptoms such as flatulence, nausea, vomiting, fatigue, malaise, and weight loss occur."
Case report listing fatigue among the symptoms of D. fragilis infection.
PMID:31050625 SUPPORT Human Clinical
"Dientamoebiasis is globally distributed and detected in a large number of subjects with diarrhea, abdominal discomfort, flatulence, fatigue and loss of appetite."
Review identifies fatigue as one of the symptoms associated with dientamoebiasis globally.
Growth 1
Weight loss OCCASIONAL HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"The most common clinical symptoms include abdominal pain, persistent diarrhoea, loss of appetite, weight loss and flatulence."
Weight loss is listed among the common clinical symptoms of D. fragilis infection.
💊

Medical Actions

4
Paromomycin therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: paromomycin CHEBI:7934 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses paromomycin (CHEBI:7934). CHEBI:7934 is a therapeutic agent from Chemical Entities of Biological Interest.
Paromomycin is an aminoglycoside antibiotic with luminal antiprotozoal activity. It has shown high eradication rates for D. fragilis and is recommended as first-line therapy in several clinical guidelines due to its narrow spectrum of activity and minimal systemic absorption.
Show evidence (2 references)
PMID:33137500 SUPPORT Human Clinical
"Our study showed paromomycin had a high efficacy for treatment of D. fragilis infections 100.0% (45/45), while caution must be used when using metronidazole 53.3% (24/40). We recommend paromomycin for empirical treatment, given its great effectiveness in our population."
Paromomycin achieved 100% eradication rate compared to 53.3% for metronidazole in this Italian cohort.
PMID:32155096 SUPPORT Human Clinical
"Paromomycin or clioquinol are antibiotics of choice based on their small spectrum of activity, fewer side effects, and better eradication rates than metronidazole."
Systematic review recommends paromomycin over metronidazole for D. fragilis treatment in children based on better eradication and fewer side effects.
Metronidazole therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: metronidazole CHEBI:6909 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses metronidazole (CHEBI:6909). CHEBI:6909 is a therapeutic agent from Chemical Entities of Biological Interest.
Metronidazole is an antiprotozoal agent commonly used for D. fragilis infection. However, eradication rates are variable and often suboptimal compared to other agents.
Show evidence (2 references)
PMID:33137500 SUPPORT Human Clinical
"Our study showed paromomycin had a high efficacy for treatment of D. fragilis infections 100.0% (45/45), while caution must be used when using metronidazole 53.3% (24/40)."
Metronidazole showed a lower eradication rate of 53.3% compared to paromomycin at 100%, suggesting suboptimal efficacy.
PMID:39540993 SUPPORT Human Clinical
"Treated patients(n = 64) more often tested PCR negative at T1 (64.1% vs. 16.4%, p < 0.001) and T2 (67.3% vs. 5.3%, p < 0.001) compared to untreated patients."
Prospective study showing metronidazole (and clioquinol) achieve parasitological clearance, but without a corresponding improvement in clinical symptom scores (IBS-SS).
Iodoquinol therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: iodoquinol CHEBI:5950 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses iodoquinol (CHEBI:5950). CHEBI:5950 is a therapeutic agent from Chemical Entities of Biological Interest.
Iodoquinol is a luminal antiprotozoal agent that has been used for D. fragilis infections. It is an alternative to paromomycin and metronidazole.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"Treatment is recommended in symptomatic cases, and iodoquinol, tetracycline and metronidazole have been used successfully."
Iodoquinol is listed as one of the agents used successfully for treatment.
Tetracycline therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tetracycline CHEBI:27902 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tetracycline (CHEBI:27902). CHEBI:27902 is a therapeutic agent from Chemical Entities of Biological Interest.
Tetracycline has been reported as an effective treatment for D. fragilis infection in older literature. However, it is generally not recommended for children under 8 years of age due to the risk of dental staining, limiting its use in the pediatric population where D. fragilis prevalence is highest.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"Treatment is recommended in symptomatic cases, and iodoquinol, tetracycline and metronidazole have been used successfully."
Tetracycline is listed among agents used successfully for D. fragilis treatment, though it has been largely superseded by paromomycin and metronidazole in current practice.
🔬

Diagnosis

2
Stool microscopy with permanent staining
Microscopic examination of permanently stained stool smears (e.g., trichrome or iron-hematoxylin stain) to identify the characteristic binucleate trophozoites of D. fragilis. Unstained preparations are insufficient for definitive diagnosis.
Show evidence (1 reference)
PMID:10795375 SUPPORT Human Clinical
"Demonstration of the characteristic nuclear structure of D. fragilis, needed for a definitive diagnosis, cannot be achieved in unstained faecal material; therefore, permanently stained smears are essential."
Permanently stained smears are required to visualize the diagnostic nuclear morphology of D. fragilis trophozoites.
Real-time PCR detection
Molecular detection of D. fragilis DNA in stool samples using real-time PCR is a sensitive and specific diagnostic approach. PCR has increasingly replaced microscopy in some clinical settings.
Show evidence (2 references)
PMID:30165915 SUPPORT Human Clinical
"The introduction of polymerase chain reaction (PCR) is a versatile and sensitive diagnostic technique for the detection of intestinal parasites, and in some Western world countries PCR has almost completely replaced microscopic diagnostics."
PCR has become the dominant diagnostic method for D. fragilis in some Western countries due to its sensitivity.
PMID:32155096 SUPPORT Human Clinical
"Both microscopic and Real Time-PCR methods (or a combination of the two) can be used for diagnosis."
Both microscopy and RT-PCR are validated diagnostic approaches.
📊

Prevalence

2
Global
Point Prevalence 300.0–82900.0 per 100,000 >1 in 1,000
Reported prevalence of D. fragilis varies enormously worldwide, from 0.3% to 82.9% depending on the population studied and diagnostic methods used. The introduction of PCR has substantially increased detection rates.
Show evidence (1 reference)
PMID:33137500 SUPPORT Human Clinical
"The reported prevalence of D. fragilis varies worldwide in different populations between 0.3% and 82.9%, and its role as a pathogen is still unclear."
Provides the range of global prevalence estimates.
Israeli pediatric population
Point Prevalence 32500.0 per 100,000 >1 in 1,000
In a large cohort study of 36,008 children under 18 who underwent multiplex PCR testing, 32.5% were positive for D. fragilis. Despite this high prevalence, children positive for D. fragilis did not exhibit higher odds for pre- or post-test composite clinical outcomes compared to those with negative PCR results, suggesting a low positive predictive value for clinically significant disease.
Show evidence (1 reference)
PMID:39481610 SUPPORT Human Clinical
"Of 36,008 eligible children, 32.5% were positive for DF and 7.9% for Bs."
Large-scale pediatric cohort study reporting high prevalence of D. fragilis in Israeli children detected by multiplex PCR.
🦠

Infectious Agent

1
Dientamoeba fragilis
A trichomonad protozoan parasite that inhabits the human large intestine. Despite its name suggesting an amoeboid nature, it is classified as a flagellate closely related to Histomonas and Trichomonas. It exists predominantly in a trophozoite form. A cyst stage with a double-layered wall has been characterized by transmission electron microscopy in experimentally infected rodents, but has not been confirmed in human stool. Trophozoites are vulnerable to highly acidic conditions, suggesting they cannot survive gastric transit without encystment or a protective vehicle.
Dientamoeba fragilis NCBITaxon:43352 NCBI Taxonomy (NCBITaxon)
Show evidence (3 references)
PMID:27170141 SUPPORT Human Clinical
"Dientamoeba fragilis is a protozoan parasite of the human bowel, commonly reported throughout the world in association with gastrointestinal symptoms."
This comprehensive review identifies D. fragilis as a protozoan parasite of the human bowel with worldwide distribution.
PMID:10795375 SUPPORT Human Clinical
"Although originally described as an amoeboid organism, it has been reclassified as a flagellate, on the basis of a number of electron microscopic and immunological findings. Except for its lack of a flagellum, D. fragilis closely resembles Histomonas and Trichomonas."
Confirms the taxonomic reclassification of D. fragilis from amoeba to flagellate and its phylogenetic relationship to Histomonas and Trichomonas.
PMID:38250789 SUPPORT Model Organism
"These studies of cysts showed a clear cyst wall surrounding an encysted parasite. The cyst wall was double layered with an outer fibrillar layer and an inner layer enclosing the parasite. Hydrogenosomes, endoplasmic reticulum and nuclei were present in the cysts. Pelta-axostyle structures, costa..."
Transmission electron microscopy of D. fragilis cysts obtained from mice and rats reveals detailed ultrastructure including a double-layered cyst wall and preserved organelles, providing evidence for the cyst life cycle stage.
↔️

Transmission

2
Co-transmission via Enterobius vermicularis eggs
A co-transmission hypothesis proposes that D. fragilis is carried within the eggs of the pinworm Enterobius vermicularis. D. fragilis DNA has been detected inside surface-sterilized E. vermicularis eggs from co-infected patients, and the higher-than-expected coincidence of D. fragilis and pinworm infections supports this mechanism. Because trophozoites are vulnerable to gastric acid and a human cyst stage has not been demonstrated, helminth egg vectoring provides a plausible route for surviving transit through the upper GI tract.
Show evidence (3 references)
PMID:23893951 SUPPORT Human Clinical
"we detected D. fragilis DNA in 18 (85%) of 21 samples of E. vermicularis eggs collected from patients harbouring D. fragilis in faeces. This finding supports the hypothesis that E. vermicularis may have an important role in the transmission of D. fragilis."
Detection of D. fragilis DNA within the majority of E. vermicularis eggs from co-infected patients supports the pinworm co-transmission hypothesis.
PMID:10795375 SUPPORT Human Clinical
"a resistant cyst stage has not been demonstrated and it is unlikely that its trophozoites can survive successfully outside the human host. As a consequence of its higher than anticipated coincidence of infection with Enterobius vermicularis, transmission may occur via ova of this pinworm."
Notes that the lack of a demonstrated cyst stage makes pinworm co-transmission a plausible explanation for D. fragilis spread.
PMID:38250789 SUPPORT Model Organism
"We provide evidence that trophozoites of D. fragilis are vulnerable to highly acidic conditions."
Demonstrates that trophozoites cannot withstand gastric pH, supporting the need for a protective vehicle such as helminth eggs for successful oral transmission.
Direct fecal-oral transmission via cysts
Direct person-to-person fecal-oral transmission has been proposed as an alternative to the pinworm co-transmission hypothesis. The identification of a cyst stage of D. fragilis in rodents infected with a human isolate implies a life cycle similar to most other intestinal protistan parasites, where environmentally resistant cysts are shed in feces and ingested by a new host. The cyst wall may protect the organism during gastric transit, though this stage has not yet been confirmed in human infections.
As of 2024, cysts of D. fragilis have been identified only in experimentally infected mice and rats. No cyst stage has been confirmed in human stool samples. This limits the evidence for direct fecal-oral transmission in humans, though it remains a plausible mechanism given the ultrastructural characterization of a resistant cyst wall in rodent models.
Show evidence (3 references)
PMID:24492020 SUPPORT Human Clinical
"Detection of D. fragilis DNA inside Enterobius vermicularis eggs agrees with the prediction of Dobell in 1940 that the eggs of a nematode act as a vector for transmission. However, the identification of a cyst stage of D. fragilis in the stool of rodents infected with a human isolate has also..."
Discusses the cyst stage identified in rodent models as an alternative transmission mechanism to helminth egg vectoring.
PMID:38250789 SUPPORT Model Organism
"These studies of cysts showed a clear cyst wall surrounding an encysted parasite. The cyst wall was double layered with an outer fibrillar layer and an inner layer enclosing the parasite."
Characterization of a double-layered cyst wall in rodent-derived cysts supports the existence of an environmentally resistant stage that could facilitate direct fecal-oral transmission.
PMID:21349214 NO_EVIDENCE Human Clinical
"Dientamoeba fragilis is an inhabitant of the human bowel and is associated with gastrointestinal illness. Despite its discovery over a century ago, the details of Dientamoeba's life cycle are unclear and its mode of transmission is unknown."
Reviews the unresolved nature of D. fragilis transmission, including the possibility of direct fecal-oral spread.
🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Dientamoebiasis:

Irritable bowel syndrome MONDO:0005052
Overlapping Features IBS presents with chronic or recurrent abdominal pain, bloating, and altered bowel habits, closely overlapping with dientamoebiasis symptoms. D. fragilis is known to cause IBS-like symptoms and may be misdiagnosed as IBS when stool parasitology is not performed. A meta-analysis found no significant association between D. fragilis and IBS (OR 1.13, 95% CI 0.22-5.72), suggesting the two are distinct conditions with overlapping presentations.
Distinguishing Features
  • IBS is a diagnosis of exclusion with no identifiable infectious agent
  • Stool microscopy or PCR can identify D. fragilis trophozoites, whereas IBS workup is parasitology-negative
  • Whether eradicating D. fragilis resolves symptoms is contested; randomized and prospective studies in this entry found parasitological clearance without corresponding symptom improvement, so treatment response does not reliably distinguish the two
Show evidence (4 references)
PMID:17070814 SUPPORT Human Clinical
"Dientamoeba fragilis is known to cause IBS-like symptoms and has a propensity to cause chronic infections but its diagnosis relies on microscopy of stained smears, which many laboratories do not perform, thereby leading to the misdiagnosis of dientamoebiasis as IBS."
Demonstrates that D. fragilis can mimic IBS and may be misdiagnosed when parasitological testing is not performed.
PMID:28668983 SUPPORT Human Clinical
"this association was not observed for D. fragilis infection (OR, 1.13; 95% CI, 0.22-5.72)."
Meta-analysis found no significant association between D. fragilis and IBS, supporting the view that they are distinct conditions with overlapping symptoms.
PMID:39540993 SUPPORT Human Clinical
"A clear and significant correlation between parasitological cure and decline of clinical complaints as reported by the participants could not be established."
Prospective study showing that eradicating D. fragilis did not improve IBS-severity scores, reinforcing the distinction between dientamoebiasis and IBS and suggesting clinical overlap without causal relationship.
+ 1 more reference
Giardiasis MONDO:0001103
Overlapping Features Giardia intestinalis infection presents with diarrhea, abdominal cramps, bloating, and flatulence, symptoms largely indistinguishable from dientamoebiasis on clinical grounds alone. Both are protozoal infections of the intestinal tract transmitted via the fecal-oral route.
Distinguishing Features
  • Giardia primarily affects the small intestine, D. fragilis the large intestine
  • Giardia has a well-characterized cyst-trophozoite cycle with environmentally resistant cysts
  • Giardia can cause steatorrhea and malabsorption, which are uncommon in dientamoebiasis
  • Specific stool antigen tests and PCR can differentiate the two organisms
Show evidence (1 reference)
PMID:17070814 SUPPORT Human Clinical
"Clinical manifestations of Giardia intestinalis infection also vary from asymptomatic carriage to acute and chronic diarrhoea with abdominal pain. These IBS-like symptoms can be continuous, intermittent, sporadic or recurrent, sometimes lasting years without correct diagnosis."
Demonstrates that Giardia infection presents with symptoms overlapping with both IBS and D. fragilis, requiring parasitological differentiation.
Blastocystis infection Not Yet Curated MONDO:0005671
Overlapping Features Blastocystis sp. is a common intestinal protozoan frequently co-detected with D. fragilis. Both cause nonspecific gastrointestinal symptoms and their pathogenic significance is debated. Co-infection is common, and distinguishing the causative agent requires species-level identification.
Distinguishing Features
  • Blastocystis has distinct morphological forms (vacuolar, granular, cyst) identifiable on microscopy
  • Blastocystis shows stronger epidemiological association with IBS than D. fragilis
  • Co-infection with both organisms is frequent and requires species-level identification
Show evidence (3 references)
PMID:28668983 SUPPORT Human Clinical
"Individuals with Blastocystis infection were found to have a positive association with IBS (OR, 2.19; 95% CI, 1.54-3.13), while this association was not observed for D. fragilis infection (OR, 1.13; 95% CI, 0.22-5.72)."
Meta-analysis distinguishing the epidemiological profiles of Blastocystis and D. fragilis in relation to IBS.
PMID:33137500 SUPPORT Human Clinical
"32 patients were co-infected with B. hominis (37.7%) and three with G. lamblia (3.5%)."
High rate of co-infection with Blastocystis hominis in D. fragilis-positive patients highlights the need to differentiate the causative agent.
PMID:39052010 SUPPORT Human Clinical
"Only the concomitant presence of Blastocystis sp. in stools was significantly more frequent in the D. fragilis group (uni- and multivariate analysis)."
Confirms a significant association between D. fragilis and Blastocystis co-infection, reinforcing the importance of distinguishing between these two organisms when evaluating gastrointestinal symptoms.
Amoebiasis Not Yet Curated MONDO:0019028
Overlapping Features Entamoeba histolytica infection can cause symptoms ranging from mild diarrhea to severe dysenteric colitis. Non-dysenteric amoebic colitis may closely mimic dientamoebiasis with chronic diarrhea and abdominal pain.
Distinguishing Features
  • E. histolytica can cause invasive disease with bloody dysentery and liver abscess
  • Trophozoites of E. histolytica contain ingested red blood cells on microscopy
  • D. fragilis trophozoites are characteristically binucleate
  • Specific antigen tests and PCR can distinguish the species
Show evidence (1 reference)
PMID:17070814 SUPPORT Human Clinical
"clinical diagnosis of amebiasis is often difficult because symptoms of patients with IBS may closely mimic those patients with non-dysenteric amoebic colitis."
Demonstrates diagnostic overlap between non-dysenteric amoebiasis and other causes of chronic GI symptoms including dientamoebiasis.
Celiac disease MONDO:0005130
Overlapping Features Celiac disease can present with chronic diarrhea, abdominal pain, bloating, and fatigue, overlapping with dientamoebiasis. Clinical guidelines recommend excluding celiac disease before attributing symptoms to D. fragilis.
Distinguishing Features
  • Celiac disease involves gluten-triggered autoimmune enteropathy with villous atrophy
  • Serological markers (anti-tTG, anti-EMA antibodies) are absent in dientamoebiasis
  • Celiac disease affects the small intestine, not the colon
  • Symptoms in celiac disease respond to gluten-free diet, not antiprotozoal therapy
Show evidence (1 reference)
PMID:32155096 SUPPORT Human Clinical
"Treatment of D. fragilis should be withhold until other causes like celiac disease have been excluded."
Clinical guideline recommends excluding celiac disease before attributing GI symptoms to D. fragilis and initiating treatment.
🔬

Clinical Trials

2
NCT01314976 PHASE_IV COMPLETED
Randomized, placebo-controlled, double-blinded clinical trial evaluating the clinical effect of metronidazole (40 mg/kg/day for 10 days) in D. fragilis-infected children with gastrointestinal complaints in Denmark. This was the first controlled trial of metronidazole versus placebo for dientamoebiasis.
Target Phenotypes: Diarrhea HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology. Abdominal pain HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
clinicaltrials:NCT01314976 SUPPORT
"To determine the clinical effect of metronidazole in DF-infected children with gastrointestinal complaints, where no other aetiology is known and no other gastrointestinal pathogens could be shown."
First placebo-controlled RCT specifically testing metronidazole for dientamoebiasis in children, addressing the critical evidence gap around treatment efficacy.
PMID:24647023 SUPPORT Human Clinical
"These findings do not provide evidence to support routine metronidazole treatment of D. fragilis positive children with chronic gastrointestinal symptoms."
Published results of this trial (96 participants) showed metronidazole did not improve gastrointestinal symptom scores versus placebo despite achieving parasitological clearance, with eradication rates declining rapidly after treatment cessation.
NCT06907498 NOT_APPLICABLE RECRUITING
Superiority double-blind, randomized controlled trial (COMFORTER Trial) comparing paromomycin versus metronidazole for symptomatic D. fragilis infection in adults. Primary outcome is clinical improvement or resolution; secondary outcomes include microbiological eradication, quality of life, and adverse events. Plans to enroll 60 patients (30 per arm).
Target Phenotypes: Diarrhea HP:0002014 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Diarrhea (HP:0002014). HP:0002014 is a phenotype from the Human Phenotype Ontology. Abdominal pain HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT06907498 SUPPORT
"we aim to perform a double blind, randomized controlled trial, evaluating the clinical and microbiological efficacy of paromomycin versus metronidazole for the treatment of symptomatic adults with PCR positive dientamoeba fragilis."
Head-to-head RCT comparing the two most commonly used treatments for D. fragilis, directly relevant to resolving the treatment efficacy debate.
{ }

Source YAML

click to show 
name: Dientamoebiasis
creation_date: '2026-02-12T23:17:11Z'
synonyms:
- Dientamoeba fragilis infection
- D. fragilis infection
category: Infectious Disease
description: >-
  Dientamoebiasis is a parasitic infection of the large intestine caused by the
  protozoan Dientamoeba fragilis. It is commonly reported worldwide in association
  with gastrointestinal symptoms including diarrhea, abdominal pain, and flatulence,
  though its pathogenicity remains debated. Transmission is thought to occur via the
  fecal-oral route, possibly facilitated by helminth eggs such as those of
  Enterobius vermicularis (pinworm). Clinical outcomes range from asymptomatic
  carriage to chronic gastrointestinal illness.
disease_term:
  term:
    id: MONDO:0024608
    label: dientamoebiasis
  preferred_term: Dientamoebiasis
parents:
- Protozoal infection
- Gastrointestinal infection
infectious_agent:
- name: Dientamoeba fragilis
  infectious_agent_term:
    preferred_term: Dientamoeba fragilis
    term:
      id: NCBITaxon:43352
      label: Dientamoeba fragilis
  description: >-
    A trichomonad protozoan parasite that inhabits the human large intestine.
    Despite its name suggesting an amoeboid nature, it is classified as a flagellate
    closely related to Histomonas and Trichomonas. It exists predominantly in a
    trophozoite form. A cyst stage with a double-layered wall has been
    characterized by transmission electron microscopy in experimentally infected
    rodents, but has not been confirmed in human stool. Trophozoites are
    vulnerable to highly acidic conditions, suggesting they cannot survive
    gastric transit without encystment or a protective vehicle.
  evidence:
  - reference: PMID:27170141
    reference_title: "Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dientamoeba fragilis is a protozoan parasite of the human bowel, commonly
      reported throughout the world in association with gastrointestinal symptoms.
    explanation: >-
      This comprehensive review identifies D. fragilis as a protozoan parasite
      of the human bowel with worldwide distribution.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although originally described as an amoeboid organism, it has been
      reclassified as a flagellate, on the basis of a number of electron microscopic
      and immunological findings. Except for its lack of a flagellum, D. fragilis
      closely resembles Histomonas and Trichomonas.
    explanation: >-
      Confirms the taxonomic reclassification of D. fragilis from amoeba to
      flagellate and its phylogenetic relationship to Histomonas and Trichomonas.
  - reference: PMID:38250789
    reference_title: "Observations on the transmission of Dientamoeba fragilis and the cyst life cycle stage."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These studies of cysts showed a clear cyst wall surrounding an encysted
      parasite. The cyst wall was double layered with an outer fibrillar layer and
      an inner layer enclosing the parasite. Hydrogenosomes, endoplasmic reticulum
      and nuclei were present in the cysts. Pelta-axostyle structures, costa and
      axonemes were identifiable and internal flagellar axonemes were present.
    explanation: >-
      Transmission electron microscopy of D. fragilis cysts obtained from mice
      and rats reveals detailed ultrastructure including a double-layered cyst wall
      and preserved organelles, providing evidence for the cyst life cycle stage.
agent_life_cycle:
  description: >-
    Dientamoeba fragilis is recorded here with the human large intestine as its
    only established host. Its life cycle is genuinely unsettled: the
    trophozoite is the form found in people and is not thought to survive
    outside them, a cyst stage has been characterized only in experimentally
    infected rodents, and carriage inside pinworm eggs is a hypothesis rather
    than a demonstrated route.
  hosts:
  - preferred_term: Homo sapiens
    role: >-
      Only established host; the trophozoite inhabits the large intestine and is
      not thought to survive outside the human host
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  - preferred_term: pinworm
    role: >-
      Proposed egg-carriage vehicle, not an established host; development of the
      parasite inside the pinworm has not been demonstrated
    term:
      id: NCBITaxon:51028
      label: Enterobius vermicularis
  vectors:
  - Pinworm (Enterobius vermicularis) eggs, a proposed and unconfirmed carriage vehicle
  life_cycle_stages:
  - name: Trophozoite stage in the human large intestine
    life_cycle_stage_term:
      preferred_term: trophozoite stage
      term:
        id: OPL:0000057
        label: trophozoite stage
    description: >-
      The trophozoite is the form found in human stool and is the predominant
      stage of the organism; it is not thought to survive outside the host.
    evidence:
    - reference: PMID:10795375
      reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a resistant cyst stage has not been demonstrated and it is unlikely that its trophozoites can survive successfully outside the human host"
      explanation: >-
        Supports the trophozoite as the human-host stage and its inability to
        persist outside the host. Copied from the transmission block with its
        grading unchanged.
  - name: Cyst stage, demonstrated only in experimentally infected rodents
    description: >-
      A double-walled cyst has been characterized by electron microscopy in mice
      and rats infected with a human isolate. No cyst stage has been confirmed
      in human stool, so this stage is recorded as rodent-only.
    evidence:
    - reference: PMID:38250789
      reference_title: Observations on the transmission of Dientamoeba fragilis and the cyst life cycle stage.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: "We also investigated further the ultrastructure of D. fragilis cysts obtained from mice and rats by transmission electron microscopy."
      explanation: >-
        Establishes that the cysts examined came from rodents, which is why this
        stage is recorded as demonstrated in rodents rather than in humans.
  evidence:
  - reference: PMID:27170141
    reference_title: "Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The details of its life cycle and mode of transmission are not completely known, and its potential as a human pathogen is debated within the scientific community."
    explanation: >-
      Supports recording this life cycle as incomplete, which is why only the
      human trophozoite stage and the rodent-demonstrated cyst stage are listed.
  notes: >-
    No animal reservoir of importance is established for D. fragilis, so none is
    recorded. The pinworm is listed as a proposed carriage vehicle rather than a
    host because the evidence for it is D. fragilis DNA inside surface-sterilized
    Enterobius vermicularis eggs from co-infected patients, which shows carriage
    of DNA and not parasite development; that evidence is cited in the
    transmission block. The rodents in which the cyst stage was characterized
    were experimentally infected and are not recorded as hosts.
transmission:
- name: Co-transmission via Enterobius vermicularis eggs
  description: >-
    A co-transmission hypothesis proposes that D. fragilis is carried within the
    eggs of the pinworm Enterobius vermicularis. D. fragilis DNA has been detected
    inside surface-sterilized E. vermicularis eggs from co-infected patients,
    and the higher-than-expected coincidence of D. fragilis and pinworm infections
    supports this mechanism. Because trophozoites are vulnerable to gastric acid
    and a human cyst stage has not been demonstrated, helminth egg vectoring
    provides a plausible route for surviving transit through the upper GI tract.
  evidence:
  - reference: PMID:23893951
    reference_title: "Dientamoeba fragilis DNA detection in Enterobius vermicularis eggs."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we detected D. fragilis DNA in 18 (85%) of 21 samples of E. vermicularis
      eggs collected from patients harbouring D. fragilis in faeces. This finding
      supports the hypothesis that E. vermicularis may have an important role in
      the transmission of D. fragilis.
    explanation: >-
      Detection of D. fragilis DNA within the majority of E. vermicularis eggs
      from co-infected patients supports the pinworm co-transmission hypothesis.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a resistant cyst stage has not been demonstrated and it is unlikely that
      its trophozoites can survive successfully outside the human host. As a
      consequence of its higher than anticipated coincidence of infection with
      Enterobius vermicularis, transmission may occur via ova of this pinworm.
    explanation: >-
      Notes that the lack of a demonstrated cyst stage makes pinworm
      co-transmission a plausible explanation for D. fragilis spread.
  - reference: PMID:38250789
    reference_title: "Observations on the transmission of Dientamoeba fragilis and the cyst life cycle stage."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We provide evidence that trophozoites of D. fragilis are vulnerable to
      highly acidic conditions.
    explanation: >-
      Demonstrates that trophozoites cannot withstand gastric pH, supporting
      the need for a protective vehicle such as helminth eggs for successful
      oral transmission.
- name: Direct fecal-oral transmission via cysts
  description: >-
    Direct person-to-person fecal-oral transmission has been proposed as an
    alternative to the pinworm co-transmission hypothesis. The identification
    of a cyst stage of D. fragilis in rodents infected with a human isolate
    implies a life cycle similar to most other intestinal protistan parasites,
    where environmentally resistant cysts are shed in feces and ingested by a
    new host. The cyst wall may protect the organism during gastric transit,
    though this stage has not yet been confirmed in human infections.
  notes: >-
    As of 2024, cysts of D. fragilis have been identified only in
    experimentally infected mice and rats. No cyst stage has been confirmed
    in human stool samples. This limits the evidence for direct fecal-oral
    transmission in humans, though it remains a plausible mechanism given
    the ultrastructural characterization of a resistant cyst wall in rodent
    models.
  evidence:
  - reference: PMID:24492020
    reference_title: "Transmission of Dientamoeba fragilis: pinworm or cysts?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Detection of D. fragilis DNA inside Enterobius vermicularis eggs agrees
      with the prediction of Dobell in 1940 that the eggs of a nematode act as a
      vector for transmission. However, the identification of a cyst stage of D.
      fragilis in the stool of rodents infected with a human isolate has also been
      reported, and this implies a life cycle similar to those of most other
      intestinal protistan parasites.
    explanation: >-
      Discusses the cyst stage identified in rodent models as an alternative
      transmission mechanism to helminth egg vectoring.
  - reference: PMID:38250789
    reference_title: "Observations on the transmission of Dientamoeba fragilis and the cyst life cycle stage."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These studies of cysts showed a clear cyst wall surrounding an encysted
      parasite. The cyst wall was double layered with an outer fibrillar layer and
      an inner layer enclosing the parasite.
    explanation: >-
      Characterization of a double-layered cyst wall in rodent-derived cysts
      supports the existence of an environmentally resistant stage that could
      facilitate direct fecal-oral transmission.
  - reference: PMID:21349214
    reference_title: "The ambiguous life of Dientamoeba fragilis: the need to investigate current hypotheses on transmission."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dientamoeba fragilis is an inhabitant of the human bowel and is associated
      with gastrointestinal illness. Despite its discovery over a century ago, the
      details of Dientamoeba's life cycle are unclear and its mode of transmission
      is unknown.
    explanation: >-
      Reviews the unresolved nature of D. fragilis transmission, including the
      possibility of direct fecal-oral spread.
pathophysiology:
- name: Trophozoite colonization of colonic mucosa
  description: >-
    Dientamoeba fragilis trophozoites establish residence in the lumen and on
    the mucosal surface of the large intestine. The organism lacks a well-established
    cyst stage in humans, so trophozoites represent the primary parasitic form
    in the colon. Colonization may be facilitated by ingestion of contaminated
    pinworm eggs harboring viable D. fragilis organisms.
  cell_types:
  - preferred_term: Epithelial cell of large intestine
    term:
      id: CL:0002253
      label: epithelial cell of large intestine
  locations:
  - preferred_term: Large intestine
    term:
      id: UBERON:0000059
      label: large intestine
  evidence:
  - reference: PMID:27170141
    reference_title: "Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dientamoeba fragilis is a protozoan parasite of the human bowel, commonly
      reported throughout the world in association with gastrointestinal symptoms.
    explanation: >-
      Confirms D. fragilis colonizes the human bowel.
  downstream:
  - target: Mucosal inflammatory response
    description: >-
      Trophozoite colonization of the colonic mucosa triggers local host
      inflammatory and immune responses.
- name: Mucosal inflammatory response
  description: >-
    Colonization by D. fragilis trophozoites is hypothesized to elicit a host
    immune response involving mucosal inflammation. D. fragilis is non-invasive
    and the precise virulence factors are poorly characterized; a mucosal
    inflammatory mechanism is inferred from the clinical symptom association
    rather than demonstrated histologically, and pathogenicity itself remains
    contested (see notes). Peripheral eosinophilia has been observed in some
    patients, suggesting a possible Th2-skewed or allergic-type immune component.
  cell_types:
  - preferred_term: Epithelial cell of large intestine
    term:
      id: CL:0002253
      label: epithelial cell of large intestine
  - preferred_term: Mature eosinophil
    term:
      id: CL:0000041
      label: mature eosinophil
  biological_processes:
  - preferred_term: Inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: Defense response to protozoan
    modifier: INCREASED
    term:
      id: GO:0042832
      label: defense response to protozoan
  locations:
  - preferred_term: Large intestine
    term:
      id: UBERON:0000059
      label: large intestine
  evidence:
  - reference: PMID:21637013
    reference_title: "A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Usually, carriage of Dientamoeba is associated with symptoms such as
      abdominal pain and diarrhea. Moreover, antimicrobial therapy followed by
      resolution of symptoms coincides with the eradication of Dientamoeba.
    explanation: >-
      Supports the pathogenic role of D. fragilis by linking carriage to symptoms
      and symptom resolution to eradication after treatment.
  - reference: PMID:23759351
    reference_title: "Dientamoeba fragilis: a family cluster of disease associated with marked peripheral eosinophilia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a familial cluster of D. fragilis associated with marked
      peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis
      infection should be considered in the setting of unexplained eosinophilia.
    explanation: >-
      Reports marked eosinophilia in D. fragilis infection, suggesting an
      eosinophilic inflammatory component to the host response.
  - reference: PMID:40153748
    reference_title: "Parasite load as a marker of pathogenicity in Dientamoeba fragilis infections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proportion of individuals with D fragilis and a parasite load less
      than 1 trophozoite per field was higher in asymptomatic individuals (controls)
      than in symptomatic cases (47.7% vs 3.1%, respectively) (P < .001). Parasite
      load is associated with the presence of gastrointestinal symptoms, supporting
      the pathogenicity of D fragilis.
    explanation: >-
      Case-control study demonstrating a dose-dependent relationship between
      parasite load and gastrointestinal symptoms, supporting a pathogenic role
      for D. fragilis. The paper does not address the underlying mucosal
      mechanism, which remains uncharacterized.
  - reference: PMID:39052010
    reference_title: "No evidence of pathogenicity of Dientamoeba fragilis following detection in stools: A case-control study."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      no significant difference was observed in the frequency of clinical signs
      between the 36 patients who tested positive for Dientamoeba fragilis PCR in
      their stools and the 72 control patients who were PCR negative for this
      protozoan.
    explanation: >-
      Case-control study found no evidence of pathogenicity, with no significant
      clinical differences between D. fragilis carriers and controls, suggesting
      D. fragilis may be a commensal of the digestive tract.
  - reference: PMID:39540993
    reference_title: "A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No difference in decline in IBS-SS was seen comparing the treatment and
      non-treatment groups at T1 (p = 0.403) or T2 (p = 1.00).
    explanation: >-
      Despite achieving parasitological clearance with treatment, no correlation
      between parasitological cure and clinical symptom improvement was
      established, challenging the causal role of D. fragilis in symptom generation.
  downstream:
  - target: Altered intestinal motility and secretion
    description: >-
      Mucosal inflammation leads to disrupted colonic motility and
      increased secretory activity producing gastrointestinal symptoms.
  - target: Systemic immune activation
    description: >-
      In some patients the inflammatory response extends beyond the gut,
      producing peripheral eosinophilia and cutaneous manifestations.
  notes: >-
    The pathogenicity of D. fragilis remains debated. Some case-control studies
    find no significant difference in clinical signs between D. fragilis-positive
    and -negative patients regardless of parasite load, suggesting it may be a
    commensal of the digestive tract. Others demonstrate a dose-dependent
    association between parasite load and symptoms. Context-dependent factors
    such as co-infections (especially Blastocystis sp.), host immunity, and
    microbiome composition may determine clinical outcomes.
- name: Altered intestinal motility and secretion
  description: >-
    Colonic mucosal inflammation caused by D. fragilis leads to altered
    intestinal motility and increased secretory activity. This manifests
    clinically as diarrhea, abdominal pain, flatulence, and nausea. The
    mechanisms likely involve local release of inflammatory mediators that
    affect smooth muscle contractility and epithelial ion transport.
  biological_processes:
  - preferred_term: Inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: Large intestine
    term:
      id: UBERON:0000059
      label: large intestine
  downstream:
  - target: Abdominal pain
    description: Altered colonic motility can manifest as abdominal pain.
  - target: Diarrhea
    description: Increased secretory activity and altered colonic motility can manifest as diarrhea.
  - target: Flatulence
    description: Intestinal dysfunction can manifest as flatulence.
  - target: Nausea
    description: Intestinal dysfunction can manifest as nausea.
  - target: Anorexia
    description: Symptomatic intestinal infection can reduce appetite.
  - target: Weight loss
    description: Persistent gastrointestinal symptoms can be accompanied by weight loss.
  - target: Fatigue
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Persistent symptomatic infection can manifest as fatigue.
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Lists the gastrointestinal symptoms resulting from intestinal
      dysfunction in D. fragilis infection.
- name: Systemic immune activation
  description: >-
    In a subset of patients, the immune response to D. fragilis extends
    beyond the intestinal mucosa, resulting in peripheral eosinophilia and
    occasionally cutaneous manifestations such as urticaria and pruritus.
    This may reflect a systemic Th2-type response or IgE-mediated
    hypersensitivity to parasite antigens.
  cell_types:
  - preferred_term: Mature eosinophil
    term:
      id: CL:0000041
      label: mature eosinophil
  biological_processes:
  - preferred_term: Innate immune response
    modifier: DYSREGULATED
    term:
      id: GO:0045087
      label: innate immune response
  downstream:
  - target: Peripheral eosinophilia
    description: Systemic immune activation can present as peripheral eosinophilia.
  - target: Pruritus
    description: Systemic immune activation can include pruritus.
  - target: Urticaria
    description: Systemic immune activation can include urticaria.
  evidence:
  - reference: PMID:23759351
    reference_title: "Dientamoeba fragilis: a family cluster of disease associated with marked peripheral eosinophilia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a familial cluster of D. fragilis associated with marked
      peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis
      infection should be considered in the setting of unexplained eosinophilia.
    explanation: >-
      Demonstrates systemic immune activation with marked eosinophilia
      extending beyond the intestinal mucosa.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Occasionally, eosinophilia, urticaria and pruritus have been described.
    explanation: >-
      Documents extra-intestinal manifestations including eosinophilia,
      urticaria, and pruritus consistent with systemic immune activation.
phenotypes:
- name: Abdominal pain
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
    located_in:
      preferred_term: Large intestine
      term:
        id: UBERON:0000059
        label: large intestine
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%,
      watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%.
    explanation: >-
      Abdominal pain was the most prevalent symptom among D. fragilis-positive
      patients in this Italian cohort.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Review identifies abdominal pain as one of the most common symptoms.
- name: Diarrhea
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:29404747
    reference_title: "Does Dientamoeba fragilis cause diarrhea? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Data from seven studies of specific populations reported that 22% had D.
      fragilis in stools of which only 23% had diarrhea. Eleven studies of stool
      samples submitted to laboratories reported that 4.3% of individuals had D.
      fragilis of which 54% had diarrhea.
    explanation: >-
      Diarrhea is frequently reported in D. fragilis carriers presenting to
      laboratories, though prevalence varies by study setting. Evidence that
      D. fragilis causes diarrhea is inconclusive.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Review identifies persistent diarrhea as one of the most common symptoms
      associated with D. fragilis infection.
- name: Flatulence
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Flatulence
    term:
      id: HP:0033589
      label: Flatulence
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Flatulence is listed among the most common clinical symptoms.
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%,
      watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%.
    explanation: >-
      Meteorism (abdominal bloating/flatulence) was reported at 16.5% in this cohort.
- name: Nausea
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%,
      watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%.
    explanation: >-
      Nausea and lack of appetite were reported at 14.1% of D. fragilis-positive patients.
- name: Anorexia
  category: Constitutional
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Anorexia
    term:
      id: HP:0002039
      label: Anorexia
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Loss of appetite is identified as a common clinical symptom.
- name: Weight loss
  category: Constitutional
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most common clinical symptoms include abdominal pain, persistent
      diarrhoea, loss of appetite, weight loss and flatulence.
    explanation: >-
      Weight loss is listed among the common clinical symptoms of D. fragilis infection.
- name: Peripheral eosinophilia
  category: Hematologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Eosinophilia
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  evidence:
  - reference: PMID:23759351
    reference_title: "Dientamoeba fragilis: a family cluster of disease associated with marked peripheral eosinophilia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report a familial cluster of D. fragilis associated with marked
      peripheral eosinophilia and gastrointestinal symptoms. Dientamoeba fragilis
      infection should be considered in the setting of unexplained eosinophilia.
    explanation: >-
      Case report of a family cluster showing marked peripheral eosinophilia
      associated with D. fragilis infection.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Occasionally, eosinophilia, urticaria and pruritus have been described.
    explanation: >-
      Review notes occasional eosinophilia in D. fragilis infection.
- name: Pruritus
  category: Dermatologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
    located_in:
      preferred_term: Skin of body
      term:
        id: UBERON:0002097
        label: skin of body
  notes: >-
    Anal itching (pruritus ani) has been reported as a surprisingly prevalent
    symptom in some studies, potentially related to co-infection with Enterobius
    vermicularis.
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%,
      watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%.
    explanation: >-
      Anal itching was the second most prevalent symptom at 27.1%, which was
      described as unexpectedly common.
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Occasionally, eosinophilia, urticaria and pruritus have been described.
    explanation: >-
      Pruritus is noted as an occasional feature of D. fragilis infection.
- name: Urticaria
  category: Dermatologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Urticaria
    term:
      id: HP:0001025
      label: Urticaria
    located_in:
      preferred_term: Skin of body
      term:
        id: UBERON:0002097
        label: skin of body
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Occasionally, eosinophilia, urticaria and pruritus have been described.
    explanation: >-
      Urticaria is reported as an occasional feature of D. fragilis infection.
- name: Fatigue
  category: Constitutional
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:8794799
    reference_title: "Dientamoeba fragilis. An unusual intestinal pathogen."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primarily characterized by diarrhea and abdominal pain, other symptoms
      such as flatulence, nausea, vomiting, fatigue, malaise, and weight loss
      occur.
    explanation: >-
      Case report listing fatigue among the symptoms of D. fragilis infection.
  - reference: PMID:31050625
    reference_title: "The importance of considering the neglected intestinal protozoan parasite Dientamoeba fragilis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dientamoebiasis is globally distributed and detected in a large number of
      subjects with diarrhea, abdominal discomfort, flatulence, fatigue and loss
      of appetite.
    explanation: >-
      Review identifies fatigue as one of the symptoms associated with
      dientamoebiasis globally.
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_low: 300.0
  rate_high: 82900.0
  percentage: 0.3-82.9
  notes: >-
    Reported prevalence of D. fragilis varies enormously worldwide, from 0.3%
    to 82.9% depending on the population studied and diagnostic methods used.
    The introduction of PCR has substantially increased detection rates.
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The reported prevalence of D. fragilis varies worldwide in different
      populations between 0.3% and 82.9%, and its role as a pathogen is still
      unclear.
    explanation: >-
      Provides the range of global prevalence estimates.
- population: Israeli pediatric population
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 32500.0
  percentage: 32.5
  notes: >-
    In a large cohort study of 36,008 children under 18 who underwent multiplex
    PCR testing, 32.5% were positive for D. fragilis. Despite this high
    prevalence, children positive for D. fragilis did not exhibit higher odds
    for pre- or post-test composite clinical outcomes compared to those with
    negative PCR results, suggesting a low positive predictive value for
    clinically significant disease.
  evidence:
  - reference: PMID:39481610
    reference_title: "High rates of Dientamoeba fragilis and Blastocystis species in children's stool but minor clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of 36,008 eligible children, 32.5% were positive for DF and 7.9% for Bs.
    explanation: >-
      Large-scale pediatric cohort study reporting high prevalence of
      D. fragilis in Israeli children detected by multiplex PCR.
treatments:
- name: Paromomycin therapy
  description: >-
    Paromomycin is an aminoglycoside antibiotic with luminal antiprotozoal activity.
    It has shown high eradication rates for D. fragilis and is recommended as
    first-line therapy in several clinical guidelines due to its narrow spectrum
    of activity and minimal systemic absorption.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: paromomycin
      term:
        id: CHEBI:7934
        label: paromomycin
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study showed paromomycin had a high efficacy for treatment of D. fragilis
      infections 100.0% (45/45), while caution must be used when using metronidazole
      53.3% (24/40). We recommend paromomycin for empirical treatment, given its
      great effectiveness in our population.
    explanation: >-
      Paromomycin achieved 100% eradication rate compared to 53.3% for
      metronidazole in this Italian cohort.
  - reference: PMID:32155096
    reference_title: "Dientamoeba fragilis in children: a systematic review on diagnostic considerations and efficacy of treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Paromomycin or clioquinol are antibiotics of choice based on their small
      spectrum of activity, fewer side effects, and better eradication rates than
      metronidazole.
    explanation: >-
      Systematic review recommends paromomycin over metronidazole for D. fragilis
      treatment in children based on better eradication and fewer side effects.
- name: Metronidazole therapy
  description: >-
    Metronidazole is an antiprotozoal agent commonly used for D. fragilis infection.
    However, eradication rates are variable and often suboptimal compared to
    other agents.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: metronidazole
      term:
        id: CHEBI:6909
        label: metronidazole
  evidence:
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our study showed paromomycin had a high efficacy for treatment of D. fragilis
      infections 100.0% (45/45), while caution must be used when using metronidazole
      53.3% (24/40).
    explanation: >-
      Metronidazole showed a lower eradication rate of 53.3% compared to
      paromomycin at 100%, suggesting suboptimal efficacy.
  - reference: PMID:39540993
    reference_title: "A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treated patients(n = 64) more often tested PCR negative at T1 (64.1% vs.
      16.4%, p < 0.001) and T2 (67.3% vs. 5.3%, p < 0.001) compared to untreated
      patients.
    explanation: >-
      Prospective study showing metronidazole (and clioquinol) achieve
      parasitological clearance, but without a corresponding improvement in
      clinical symptom scores (IBS-SS).
- name: Iodoquinol therapy
  description: >-
    Iodoquinol is a luminal antiprotozoal agent that has been used for D. fragilis
    infections. It is an alternative to paromomycin and metronidazole.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: iodoquinol
      term:
        id: CHEBI:5950
        label: iodoquinol
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is recommended in symptomatic cases, and iodoquinol, tetracycline
      and metronidazole have been used successfully.
    explanation: >-
      Iodoquinol is listed as one of the agents used successfully for treatment.
- name: Tetracycline therapy
  description: >-
    Tetracycline has been reported as an effective treatment for D. fragilis
    infection in older literature. However, it is generally not recommended
    for children under 8 years of age due to the risk of dental staining,
    limiting its use in the pediatric population where D. fragilis prevalence
    is highest.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetracycline
      term:
        id: CHEBI:27902
        label: tetracycline
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment is recommended in symptomatic cases, and iodoquinol, tetracycline
      and metronidazole have been used successfully.
    explanation: >-
      Tetracycline is listed among agents used successfully for D. fragilis
      treatment, though it has been largely superseded by paromomycin and
      metronidazole in current practice.
diagnosis:
- name: Stool microscopy with permanent staining
  description: >-
    Microscopic examination of permanently stained stool smears (e.g., trichrome
    or iron-hematoxylin stain) to identify the characteristic binucleate
    trophozoites of D. fragilis. Unstained preparations are insufficient for
    definitive diagnosis.
  evidence:
  - reference: PMID:10795375
    reference_title: "Dientamoeba fragilis: the unflagellated human flagellate."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Demonstration of the characteristic nuclear structure of D. fragilis, needed
      for a definitive diagnosis, cannot be achieved in unstained faecal material;
      therefore, permanently stained smears are essential.
    explanation: >-
      Permanently stained smears are required to visualize the diagnostic
      nuclear morphology of D. fragilis trophozoites.
- name: Real-time PCR detection
  description: >-
    Molecular detection of D. fragilis DNA in stool samples using real-time PCR
    is a sensitive and specific diagnostic approach. PCR has increasingly replaced
    microscopy in some clinical settings.
  evidence:
  - reference: PMID:30165915
    reference_title: "A clinical guideline on Dientamoeba fragilis infections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The introduction of polymerase chain reaction (PCR) is a versatile and
      sensitive diagnostic technique for the detection of intestinal parasites,
      and in some Western world countries PCR has almost completely replaced
      microscopic diagnostics.
    explanation: >-
      PCR has become the dominant diagnostic method for D. fragilis in some
      Western countries due to its sensitivity.
  - reference: PMID:32155096
    reference_title: "Dientamoeba fragilis in children: a systematic review on diagnostic considerations and efficacy of treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both microscopic and Real Time-PCR methods (or a combination of the two)
      can be used for diagnosis.
    explanation: >-
      Both microscopy and RT-PCR are validated diagnostic approaches.
differential_diagnoses:
- name: Irritable bowel syndrome
  description: >-
    IBS presents with chronic or recurrent abdominal pain, bloating, and altered
    bowel habits, closely overlapping with dientamoebiasis symptoms. D. fragilis
    is known to cause IBS-like symptoms and may be misdiagnosed as IBS when
    stool parasitology is not performed. A meta-analysis found no significant
    association between D. fragilis and IBS (OR 1.13, 95% CI 0.22-5.72),
    suggesting the two are distinct conditions with overlapping presentations.
  disease_term:
    preferred_term: Irritable bowel syndrome
    term:
      id: MONDO:0005052
      label: irritable bowel syndrome
  distinguishing_features:
  - IBS is a diagnosis of exclusion with no identifiable infectious agent
  - Stool microscopy or PCR can identify D. fragilis trophozoites, whereas IBS workup is parasitology-negative
  - Whether eradicating D. fragilis resolves symptoms is contested; randomized and prospective studies in this entry found parasitological clearance without corresponding symptom improvement, so treatment response does not reliably distinguish the two
  evidence:
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dientamoeba fragilis is known to cause IBS-like symptoms and has a propensity
      to cause chronic infections but its diagnosis relies on microscopy of stained
      smears, which many laboratories do not perform, thereby leading to the
      misdiagnosis of dientamoebiasis as IBS.
    explanation: >-
      Demonstrates that D. fragilis can mimic IBS and may be misdiagnosed when
      parasitological testing is not performed.
  - reference: PMID:28668983
    reference_title: "The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      this association was not observed for D. fragilis infection (OR, 1.13; 95%
      CI, 0.22-5.72).
    explanation: >-
      Meta-analysis found no significant association between D. fragilis and IBS,
      supporting the view that they are distinct conditions with overlapping symptoms.
  - reference: PMID:39540993
    reference_title: "A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A clear and significant correlation between parasitological cure and decline
      of clinical complaints as reported by the participants could not be
      established.
    explanation: >-
      Prospective study showing that eradicating D. fragilis did not improve
      IBS-severity scores, reinforcing the distinction between dientamoebiasis
      and IBS and suggesting clinical overlap without causal relationship.
  - reference: PMID:39481610
    reference_title: "High rates of Dientamoeba fragilis and Blastocystis species in children's stool but minor clinical significance."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children positive for DF or Bs did not exhibit higher odds for pre- or
      post-test composite outcomes compared to those with all-negative PCR results,
      except for increased rates of abdominal pain and referrals for anti-TTG
      testing among DF-positive children.
    explanation: >-
      Large pediatric cohort found limited clinical significance of D. fragilis,
      with increased anti-TTG referrals among positive children suggesting
      clinicians may consider celiac disease (and by extension IBS) in the
      differential workup.
- name: Giardiasis
  description: >-
    Giardia intestinalis infection presents with diarrhea, abdominal cramps,
    bloating, and flatulence, symptoms largely indistinguishable from
    dientamoebiasis on clinical grounds alone. Both are protozoal infections
    of the intestinal tract transmitted via the fecal-oral route.
  disease_term:
    preferred_term: Giardiasis
    term:
      id: MONDO:0001103
      label: giardiasis
  distinguishing_features:
  - Giardia primarily affects the small intestine, D. fragilis the large intestine
  - Giardia has a well-characterized cyst-trophozoite cycle with environmentally resistant cysts
  - Giardia can cause steatorrhea and malabsorption, which are uncommon in dientamoebiasis
  - Specific stool antigen tests and PCR can differentiate the two organisms
  evidence:
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations of Giardia intestinalis infection also vary from
      asymptomatic carriage to acute and chronic diarrhoea with abdominal pain.
      These IBS-like symptoms can be continuous, intermittent, sporadic or
      recurrent, sometimes lasting years without correct diagnosis.
    explanation: >-
      Demonstrates that Giardia infection presents with symptoms overlapping
      with both IBS and D. fragilis, requiring parasitological differentiation.
- name: Blastocystis infection
  description: >-
    Blastocystis sp. is a common intestinal protozoan frequently co-detected
    with D. fragilis. Both cause nonspecific gastrointestinal symptoms and
    their pathogenic significance is debated. Co-infection is common, and
    distinguishing the causative agent requires species-level identification.
  disease_term:
    preferred_term: Blastocystis infectious disease
    term:
      id: MONDO:0005671
      label: Blastocystis infectious disease
  distinguishing_features:
  - Blastocystis has distinct morphological forms (vacuolar, granular, cyst) identifiable on microscopy
  - Blastocystis shows stronger epidemiological association with IBS than D. fragilis
  - Co-infection with both organisms is frequent and requires species-level identification
  evidence:
  - reference: PMID:28668983
    reference_title: "The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with Blastocystis infection were found to have a positive
      association with IBS (OR, 2.19; 95% CI, 1.54-3.13), while this association
      was not observed for D. fragilis infection (OR, 1.13; 95% CI, 0.22-5.72).
    explanation: >-
      Meta-analysis distinguishing the epidemiological profiles of Blastocystis
      and D. fragilis in relation to IBS.
  - reference: PMID:33137500
    reference_title: "Dientamoeba fragilis in the North-East of Italy: Prevalence study and treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      32 patients were co-infected with B. hominis (37.7%) and three with G.
      lamblia (3.5%).
    explanation: >-
      High rate of co-infection with Blastocystis hominis in D. fragilis-positive
      patients highlights the need to differentiate the causative agent.
  - reference: PMID:39052010
    reference_title: "No evidence of pathogenicity of Dientamoeba fragilis following detection in stools: A case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only the concomitant presence of Blastocystis sp. in stools was
      significantly more frequent in the D. fragilis group (uni- and multivariate
      analysis).
    explanation: >-
      Confirms a significant association between D. fragilis and Blastocystis
      co-infection, reinforcing the importance of distinguishing between these
      two organisms when evaluating gastrointestinal symptoms.
- name: Amoebiasis
  description: >-
    Entamoeba histolytica infection can cause symptoms ranging from mild
    diarrhea to severe dysenteric colitis. Non-dysenteric amoebic colitis
    may closely mimic dientamoebiasis with chronic diarrhea and abdominal
    pain.
  disease_term:
    preferred_term: Amoebiasis due to Entamoeba histolytica
    term:
      id: MONDO:0019028
      label: amoebiasis due to Entamoeba histolytica
  distinguishing_features:
  - E. histolytica can cause invasive disease with bloody dysentery and liver abscess
  - Trophozoites of E. histolytica contain ingested red blood cells on microscopy
  - D. fragilis trophozoites are characteristically binucleate
  - Specific antigen tests and PCR can distinguish the species
  evidence:
  - reference: PMID:17070814
    reference_title: "Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      clinical diagnosis of amebiasis is often difficult because symptoms of
      patients with IBS may closely mimic those patients with non-dysenteric
      amoebic colitis.
    explanation: >-
      Demonstrates diagnostic overlap between non-dysenteric amoebiasis
      and other causes of chronic GI symptoms including dientamoebiasis.
- name: Celiac disease
  description: >-
    Celiac disease can present with chronic diarrhea, abdominal pain, bloating,
    and fatigue, overlapping with dientamoebiasis. Clinical guidelines
    recommend excluding celiac disease before attributing symptoms to D. fragilis.
  disease_term:
    preferred_term: Celiac disease
    term:
      id: MONDO:0005130
      label: celiac disease
  distinguishing_features:
  - Celiac disease involves gluten-triggered autoimmune enteropathy with villous atrophy
  - Serological markers (anti-tTG, anti-EMA antibodies) are absent in dientamoebiasis
  - Celiac disease affects the small intestine, not the colon
  - Symptoms in celiac disease respond to gluten-free diet, not antiprotozoal therapy
  evidence:
  - reference: PMID:32155096
    reference_title: "Dientamoeba fragilis in children: a systematic review on diagnostic considerations and efficacy of treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment of D. fragilis should be withhold until other causes like celiac
      disease have been excluded.
    explanation: >-
      Clinical guideline recommends excluding celiac disease before attributing
      GI symptoms to D. fragilis and initiating treatment.
clinical_trials:
- name: NCT01314976
  phase: PHASE_IV
  status: COMPLETED
  description: >-
    Randomized, placebo-controlled, double-blinded clinical trial evaluating the
    clinical effect of metronidazole (40 mg/kg/day for 10 days) in D. fragilis-infected
    children with gastrointestinal complaints in Denmark. This was the first controlled
    trial of metronidazole versus placebo for dientamoebiasis.
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  - preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: clinicaltrials:NCT01314976
    reference_title: "Metronidazole for the Treatment of Dientamoebiasis in Children in Denmark - A Randomized, Placebo-controlled, Double-blinded Clinical Trial"
    supports: SUPPORT
    snippet: >-
      To determine the clinical effect of metronidazole in DF-infected children
      with gastrointestinal complaints, where no other aetiology is known and no
      other gastrointestinal pathogens could be shown.
    explanation: >-
      First placebo-controlled RCT specifically testing metronidazole for
      dientamoebiasis in children, addressing the critical evidence gap around
      treatment efficacy.
  - reference: PMID:24647023
    reference_title: "Metronidazole therapy for treating dientamoebiasis in children is not associated with better clinical outcomes: a randomized, double-blinded and placebo-controlled clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings do not provide evidence to support routine metronidazole
      treatment of D. fragilis positive children with chronic gastrointestinal
      symptoms.
    explanation: >-
      Published results of this trial (96 participants) showed metronidazole
      did not improve gastrointestinal symptom scores versus placebo despite
      achieving parasitological clearance, with eradication rates declining
      rapidly after treatment cessation.
- name: NCT06907498
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: >-
    Superiority double-blind, randomized controlled trial (COMFORTER Trial)
    comparing paromomycin versus metronidazole for symptomatic D. fragilis
    infection in adults. Primary outcome is clinical improvement or resolution;
    secondary outcomes include microbiological eradication, quality of life, and
    adverse events. Plans to enroll 60 patients (30 per arm).
  target_phenotypes:
  - preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  - preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: clinicaltrials:NCT06907498
    reference_title: "Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults (COMFORTER Trial) - Protocol for a Superiority Double Blind, Randomized Controlled Trial"
    supports: SUPPORT
    snippet: >-
      we aim to perform a double blind, randomized controlled trial, evaluating
      the clinical and microbiological efficacy of paromomycin versus metronidazole
      for the treatment of symptomatic adults with PCR positive dientamoeba fragilis.
    explanation: >-
      Head-to-head RCT comparing the two most commonly used treatments for
      D. fragilis, directly relevant to resolving the treatment efficacy debate.
discussions:
- discussion_id: gap_dientamoeba_pathogenicity
  prompt: >-
    Is Dientamoeba fragilis a true intestinal pathogen capable of causing
    gastrointestinal disease, or primarily a commensal organism whose
    co-detection with symptoms reflects epidemiological coincidence — and does
    Blastocystis sp. co-infection confound pathogenicity assessments?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Mucosal inflammatory response
  - pathophysiology#Trophozoite colonization of colonic mucosa
  rationale: >-
    The causal pathogenicity of D. fragilis remains unresolved. Evidence
    supporting pathogenicity: parasite load correlates dose-dependently with
    symptom severity (PMID:40153748); eosinophilia in familial clusters
    implicates an immune mechanism (PMID:23759351). Evidence against: two
    placebo-controlled trials found no clinical benefit from eradication
    therapy versus placebo or watch-and-wait (PMID:24647023;
    PMID:39540993), and a 2024 case-control study found no clinical
    differences between PCR-positive and PCR-negative groups
    (PMID:39052010). Critically, no specific invasion virulence factors,
    mucosal histological lesions, or parasite–host contact structures
    attributable to D. fragilis have been demonstrated in human tissue,
    unlike Entamoeba histolytica which has well-characterized invasion
    mechanisms. Blastocystis sp. co-infection (present in ~38% of
    D. fragilis-positive patients in one cohort, PMID:33137500) further
    confounds interpretation: Blastocystis carries a stronger
    epidemiological IBS association than D. fragilis (PMID:28668983),
    and studies that do not stratify by co-infection status cannot
    attribute symptoms to either organism alone.
  proposed_experiments:
  - experiment_id: exp_dientamoeba_mucosal_biopsy_stratified
    name: Colonoscopy with mucosal biopsy stratified by Blastocystis co-infection
    description: >-
      Recruit PCR-confirmed D. fragilis carriers (both symptomatic and
      asymptomatic) and matched PCR-negative controls, stratified by
      Blastocystis sp. co-infection status. Perform colonoscopy with mucosal
      biopsies to assess histological evidence of mucosal injury, lamina
      propria inflammation, and parasite-host interface zones. Determine
      whether any inflammatory signal is attributable to D. fragilis
      independently of Blastocystis co-infection.
  - experiment_id: exp_dientamoeba_stratified_rct
    name: Eradication RCT stratified by parasite load and Blastocystis co-infection
    description: >-
      Design a placebo-controlled eradication trial with pre-specified
      stratification by quantitative parasite load and Blastocystis
      co-infection status. Test whether treatment benefit is conditional on
      high D. fragilis burden or on the absence of Blastocystis, to
      determine whether current RCT null results reflect genuine
      commensalism or inadequate subgroup stratification.
references:
- reference: DOI:10.1007/s12144-021-01700-z
  title: The effect of Blastocystis sp. and Dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females
  findings: []
📚

References & Deep Research

References

1
DOI:10.1007/s12144-021-01700-z
The effect of Blastocystis sp. and Dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females
No top-level findings curated for this source.

Deep Research

2

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Disorder ▸

Disorder

  • Name: Dientamoebiasis
  • Category: Infectious Disease
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 59

Key Pathophysiology Nodes

  • Trophozoite colonization of colonic mucosa
  • Mucosal inflammatory response
  • Altered intestinal motility and secretion
  • Systemic immune activation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1007/s12144-021-01700-z
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 5 citations 2026-02-12T14:20:20.401927

Disease Pathophysiology Research Report

Target Disease - Disease Name: Dientamoebiasis (infection with Dientamoeba fragilis) - MONDO ID: Not confirmed in the present evidence scan - Category: Infectious Disease

Executive Summary - Current understanding of the pathophysiology of Dientamoeba fragilis remains limited and controversial. Evidence in recent literature highlights that clinical outcomes range from asymptomatic carriage to symptomatic gastrointestinal disease, and some authors argue D. fragilis may behave as a commensal in many hosts. This uncertainty directly affects mechanistic inferences, disease staging, and clinical decision-making (ganci2023theeffectof pages 13-13).

  1. Core Pathophysiology
  2. Primary mechanisms: The mechanistic basis by which Dientamoeba fragilis would cause host tissue injury or inflammation has not been clearly established in the recent literature sampled here. Contemporary sources emphasize heterogeneity in host outcomes, from potential health benefits/benign carriage to severe illness, implying that if pathogenic mechanisms exist, they may be context dependent (e.g., host factors, co-infections, microbiome state) (ganci2023theeffectof pages 13-13). Direct quote: “Health outcomes associated with … Dientamoeba fragilis are disparate and controversial, ranging from health benefits, to years of asymptomatic carriage, through to severe illness.” URL: https://doi.org/10.1007/s12144-021-01700-z; Publication date: April 2023 (ganci2023theeffectof pages 13-13).
  3. Molecular pathways: No consistent host signaling or parasite virulence pathways (e.g., cytokine profiles, barrier dysfunction, specific proteases/adhesins) are supported by the evidence retrieved here. The same 2023 source underscores ongoing debate over pathogenicity rather than delineating defined molecular injury cascades (ganci2023theeffectof pages 13-13).

  4. Cellular processes: Specific epithelial injury, mucus barrier disruption, or immune-cell activation pathways attributable to D. fragilis remain insufficiently defined in the evidence retrieved; the dominant theme is uncertainty over pathogenicity and effect size in humans (ganci2023theeffectof pages 13-13).

  5. Key Molecular Players

  6. Genes/Proteins: No parasite genes or host molecular mediators can be conclusively identified from the present evidence as causal in disease expression for dientamoebiasis (ganci2023theeffectof pages 13-13).
  7. Chemical Entities (metabolites/drugs): Not supported by the present evidence scan (ganci2023theeffectof pages 13-13).
  8. Cell Types: No specific cell-type targeting (e.g., colonocytes, goblet cells, macrophages, dendritic cells) can be confirmed from the present evidence (ganci2023theeffectof pages 13-13).

  9. Anatomical Locations: D. fragilis colonizes the large intestine; however, detailed site-specific pathology cannot be substantiated from the retrieved source (ganci2023theeffectof pages 13-13).

  10. Biological Processes (GO annotation candidates)

  11. Due to the paucity of mechanistic data in the retrieved evidence, no specific GO processes (e.g., epithelial tight junction modulation, cytokine-mediated signaling, innate immune activation) can be confidently annotated for D. fragilis pathophysiology at this time (ganci2023theeffectof pages 13-13).

  12. Cellular Components

  13. No confident assignments (e.g., apical tight junctions, mucus layer, lamina propria immune niches) are possible from the present evidence (ganci2023theeffectof pages 13-13).

  14. Disease Progression

  15. Sequence of events: A reproducible sequence from colonization to symptoms is not delineated in the retrieved evidence. The 2023 source stresses the spectrum from asymptomatic carriage to possible disease, highlighting the need for additional, mechanistic human and experimental studies (ganci2023theeffectof pages 13-13).

  16. Stages/Phases: Not defined in the present evidence (ganci2023theeffectof pages 13-13).

  17. Phenotypic Manifestations

  18. Clinical phenotypes: Reports in the literature span asymptomatic carriage to gastrointestinal complaints; however, the retrieved 2023 evidence emphasizes that “evidence that … D. fragilis are not necessarily pathogenic and are likely to be part of a diverse gut [microbiota]” is increasing (directly quoted). URL: https://doi.org/10.1007/s12144-021-01700-z; Publication date: April 2023 (ganci2023theeffectof pages 13-13).
  19. Interpretation: Given the uncertainty, phenotype-pathophysiology links (e.g., diarrhea due to epithelial inflammation) cannot be asserted with confidence from the evidence at hand (ganci2023theeffectof pages 13-13).

Expert Opinions and Analysis - A recent (2023) peer-reviewed article explicitly frames D. fragilis pathogenicity as “disparate and controversial,” and notes growing evidence for commensal status in many individuals, tempering assumptions about inherent pathogenicity and urging careful interpretation of positive tests in clinical practice (URL: https://doi.org/10.1007/s12144-021-01700-z; Apr 2023) (ganci2023theeffectof pages 13-13).

Current Applications and Real-World Implementations - Diagnostics and management: The retrieved 2023 article chiefly contextualizes D. fragilis within broader debates of commensalism versus pathogenicity and does not provide definitive, mechanism-based diagnostic biomarkers or targeted therapies. Clinical decisions may require integration of symptom profiles, exclusion of alternative causes, and cautious interpretation of detection results in light of uncertain pathogenicity (ganci2023theeffectof pages 13-13).

Relevant Statistics and Data from Recent Studies - The 2023 article is a cross-sectional retrospective study focusing on psychological symptom domains; it does not provide mechanistic pathophysiology statistics. Its key contribution is evidentiary framing: absence of a clear association between protozoan carriage and psychological symptom severity and the broader statement about contested pathogenicity (URL: https://doi.org/10.1007/s12144-021-01700-z; Apr 2023) (ganci2023theeffectof pages 13-13).

Structured Annotations (provisional; constrained by available evidence) - Gene/Protein (HGNC): None supported (ganci2023theeffectof pages 13-13) - Biological Process (GO): None supported (ganci2023theeffectof pages 13-13) - Cellular Component (GO): None supported (ganci2023theeffectof pages 13-13) - Cell Type (CL): None supported (ganci2023theeffectof pages 13-13) - Anatomical Location (UBERON): Large intestine (colon) – not explicitly documented in the retrieved excerpt; mechanistic localization cannot be substantiated here (ganci2023theeffectof pages 13-13) - Phenotype (HPO): Asymptomatic carriage vs. gastrointestinal symptoms are debated; no definitive HPO mapping from the retrieved excerpt (ganci2023theeffectof pages 13-13) - Chemical Entity (CHEBI): None supported (ganci2023theeffectof pages 13-13)

Evidence Items - Ganci M, Butt H, Tyrrell J, Suleyman E, Ball M. The effect of Blastocystis sp. and Dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females. Current Psychology. 2023 Apr;42:4017–4030. DOI: 10.1007/s12144-021-01700-z. URL: https://doi.org/10.1007/s12144-021-01700-z. Key quotes: “Health outcomes associated with Blastocystis sp. and Dientamoeba fragilis are disparate and controversial, ranging from health benefits, to years of asymptomatic carriage, through to severe illness.” “These findings add weight to the argument that Blastocystis sp. and D. fragilis are not necessarily pathogenic and are likely to be part of a diverse gut [microbiota].” (ganci2023theeffectof pages 13-13)

Limitations and Gaps - The present evidence scan captured one 2023 peer-reviewed article that frames the overarching controversy but does not provide molecular/cellular mechanisms for D. fragilis pathophysiology. Many key mechanistic topics—host immune signaling, barrier disruption, parasite virulence factors, and disease staging—remain unaddressed here due to lack of accessible full texts within this search session. Accordingly, this report is partial and emphasizes the current uncertainty documented in the 2023 source (ganci2023theeffectof pages 13-13).

Recommendations for Further Evidence Acquisition - Targeted retrieval of recent (2023–2024) mechanistic studies and reviews on: D. fragilis–epithelium interactions, cytokine/chemokine responses, barrier integrity assays, protease/adhesin characterization, transcriptomics/genomics of D. fragilis, and controlled clinical studies correlating organism burden with mucosal inflammation and symptoms. Priority should be given to primary literature with PMIDs and authoritative reviews summarizing mechanistic data.

References

  1. (ganci2023theeffectof pages 13-13): Michael Ganci, Henry Butt, Jean Tyrrell, Emra Suleyman, and Michelle Ball. The effect of blastocystis sp. and dientamoeba fragilis on psychological symptom severity in a sample of clinically diverse males and females. Current Psychology, 42:4017-4030, Apr 2023. URL: https://doi.org/10.1007/s12144-021-01700-z, doi:10.1007/s12144-021-01700-z. This article has 5 citations and is from a peer-reviewed journal.